HIV Protease

Ganodermanondiol is an HIV protease inhibitor derived from Ganoderma lucidum. It demonstrates significant anti-HIV-1 protease activity, with an IC50 of 90 μM, making it a valuable compound for antiviral research. Additionally, Ganodermanondiol exhibits strong cytoprotective effects against tert-butyl hydroperoxide-induced hepatotoxicity and showcases anticomplement activity against the classical pathway of the complement system, with an IC50 of 41.7 μM. This compound is relevant for studies focused on hepatoprotection and immune modulation.

HIV-IN-11 is a potent HIV protease inhibitor that disrupts the activity of HIV-1 protease through competitive inhibition, with a Ki of 0.049 nM. This compound effectively inhibits the replication of HIV(IIIb)-infected MT4 lymphocytes at concentrations of 25.0-50.0 nM. Demonstrating a longer half-life compared to indinavir sulfate in animal models, HIV-IN-11 represents a promising candidate for second-generation HIV treatment research.

DMP 323 is a potent, nonpeptide cyclic urea inhibitor of HIV protease, targeting both HIV-1 and HIV-2. It functions as a competitive inhibitor by blocking the cleavage of peptide substrates and the HIV-1 gag polyprotein, demonstrating robust antiviral activity. DMP 323 exhibits comparable efficacy to leading HIV protease inhibitors while remaining effective in human plasma or serum, indicating low affinity for plasma proteins. Additionally, it shows minimal inhibition of mammalian proteases at higher concentrations, underscoring its selectivity for HIV protease.

AQ148 is a selective HIV-1 protease inhibitor with a Ki value of 137 nM. It demonstrates significant inhibitory activity against aspartic proteases from HIV-1 (IC50 = 1.5 μM), HIV-2 (IC50 = 3.4 μM), and simian immunodeficiency virus (SIV) (IC50 = 5 μM). This compound is useful for research applications focused on HIV pathogenesis and the development of antiviral therapies.

20(21)-Dehydrolucidenic acid A is a triterpenoid derived from the fruiting body of Ganoderma sinense, primarily targeting HIV protease. This compound exhibits modest inhibitory activity against HIV-1 protease, making it a valuable tool in the study of HIV pathogenesis and in the development of antiviral strategies. Its unique structure offers potential insights into therapeutic applications for HIV treatment.

U-85548E is an HIV protease inhibitor that demonstrates nanomolar affinity for the HIV-1 aspartic protease. This compound has been developed through investigations into its structure-activity relationships, proving effective against both HIV-1 and HIV-2 proteases. Its binding interactions have been characterized using X-ray crystallography and molecular modeling, making it a valuable tool for research in HIV drug development and mechanistic studies of protease inhibition.

Kynostatin 272 is a potent inhibitor of the HIV protease, targeting the enzyme's active site by mimicking the substrate transition state. This mechanism effectively disrupts a critical stage in the replication cycle of the HIV virus. Kynostatin 272 serves as a valuable tool in HIV research, aiding in the development of therapeutic strategies for managing HIV and AIDS.

Stercobilin hydrochloride (mixture of isomers) serves as an HIV protease inhibitor, exhibiting a Ki value of 4 μM. This bile pigment, derived from gut bacteria metabolism, can promote pro-inflammatory responses in mouse macrophage RAW264 cells, including the upregulation of cytokines such as TNF-α and IL-1β. Applications of Stercobilin hydrochloride extend to the investigation of inflammatory processes and viral infections.

GS-9770 is an orally active inhibitor specifically targeting HIV protease, with a Ki of 0.16 nM. It demonstrates potent antiviral activity against both HIV-1 and HIV-2 strains, showing EC50 values ranging from 1.9 to 26 nM. In addition to its efficacy, GS-9770 is metabolically stable in human liver microsomes and exhibits favorable pharmacokinetic properties in Sprague Dawley rats, making it a valuable tool for research in HIV treatment.

L 756423 is a potent inhibitor of HIV protease, targeting the enzyme crucial for the maturation of infectious HIV particles. This compound exhibits significant antiviral activity, making it a valuable tool for research into HIV infection and the development of therapeutic strategies. Its effective inhibition of protease could contribute to understanding HIV lifecycle and resistance mechanisms.

R-87366 is a water-soluble inhibitor of HIV protease, demonstrating potent inhibition with a Ki value of 11 nM. This compound is instrumental in the study of human immunodeficiency virus (HIV) mechanisms and provides valuable insights for the development of antiviral therapies. R-87366 serves as a key reagent for research focused on combating HIV infections.

Lopinavir Metabolite M-1 is a potent HIV protease inhibitor with a Ki of 0.7 pM. This active metabolite exhibits significant antiviral activity in vitro, making it valuable for research on HIV treatment and drug resistance mechanisms. Its efficacy in inhibiting HIV replication underlines its relevance in antiviral studies and therapeutic development.

HIV protease-IN-1 is a potent non-peptidic inhibitor of HIV protease, designed to interfere with the viral life cycle. Its primary mechanism involves the inhibition of HIV protease, which is essential for the processing of viral polyproteins into functional proteins. This compound holds significant potential for research applications in the development of therapeutic strategies against AIDS and HIV-related pathologies.

A-77003 is a potent HIV protease inhibitor, demonstrating an IC50 range of 0.1 to 0.2 μg/ml against both HIV-1 and HIV-2 proteases. This compound exhibits significant antiretroviral activity while maintaining low cytotoxicity in vitro, making it suitable for research applications focused on HIV treatment and therapeutic development.

Ro 31-8588 is a potent HIV protease inhibitor, exhibiting a Ki of 0.3 nM. This compound is essential for studying the role of HIV protease in viral replication and can be utilized in research focused on AIDS treatment and potential therapeutic strategies. Its high affinity makes it a valuable tool for investigating the mechanistic aspects of HIV inhibition.

2α,19α-Dihydroxy-3-oxo-urs-12-en-28-oic acid is identified as a potent inhibitor of HIV protease, exhibiting significant antiviral activity. Additionally, this compound inhibits the activation of Epstein-Barr virus early antigen (EBV-EA), demonstrating its utility in virology research. Furthermore, it displays inhibitory effects on nitric oxide production in lipopolysaccharide-activated RAW 264.7 cells, highlighting its potential applications in immunology and inflammation studies.